SARS-CoV Vaccine Efficacy in Older Mice
Author Information
Author(s): Deming D, Sheahan T, Heise M, Yount B, Davis N, Sims A, Suthar M, Harkema J, Whitmore A, Pickles R, West A, Donaldson E, Curtis K, Johnston R, Baric R
Primary Institution: University of North Carolina at Chapel Hill
Hypothesis
Can a SARS-CoV vaccine provide long-term protection in senescent mice against both homologous and heterologous strains?
Conclusion
The study identifies challenges in vaccine design for controlling future SARS-CoV zoonosis, particularly in vulnerable elderly populations.
Supporting Evidence
- VRP-S vaccines provided complete short- and long-term protection against homologous strain challenge in both young and senescent mice.
- VRP-N vaccines failed to protect from homologous or heterologous challenge and resulted in enhanced immunopathology.
- Senescent mice showed reduced neutralizing antibody responses compared to younger mice.
Takeaway
Researchers tested a vaccine for SARS-CoV in older mice and found it worked well against some strains but not all, showing that older animals might need special attention when developing vaccines.
Methodology
The study used Venezuelan equine encephalitis virus replicon particles expressing SARS-CoV proteins to vaccinate young and senescent mice, followed by challenges with homologous and heterologous SARS-CoV strains.
Potential Biases
Potential bias in the interpretation of results due to the use of a single animal model.
Limitations
The study primarily used a mouse model, which may not fully replicate human responses to SARS-CoV infection and vaccination.
Participant Demographics
Young and senescent BALB/c mice were used in the study.
Statistical Information
P-Value
0.007
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website